Adil S. Lakha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adil S. Lakha has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Alex Gordon-Weeks
3 shared publications- Alex Gordon-Weeks
Department of Oncology, University of Oxford, Oxford, UK
3 shared publications A. Gordon-Weeks
1 shared publicationAndreas Pascher
Department of General, Visceral and Transplant Surgery, University Hospital Muenster, University of Muenster , Muenster
1 shared publicationAndrew Ang
Surgical Emergency Unit, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
1 shared publicationAnisa Nutu
Unit of Hepato-Pancreato-Biliary Surgery and Abdominal Organ Transplantation, Instituto de Investigación Sanitaria Hospital Doce de Octubre (imas12) , Madrid
1 shared publication
Latest Publications
- 24 September 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (9) , e273336
Surgical management of gallbladder volvulus
An elderly female in her 80s presented to the Emergency Department with abdominal pain and vomiting, following episodes of intermittent colicky abdominal pain over the preceding 3 days. On examination she was exquisitely tender over a palpable gallbladder in the mid epigastric region. The patient underwent cross-sectional imaging suggestive of acute acalculous cholecystitis and significant hydrops with possible perforation. On review of the images, a suspicion of gallbladder volvulus resulted in emergency need for intervention. At laparoscopy, a diagnosis of gallbladder volvulus was confirmed, with a grossly distended, necrotic gallbladder noted on entry into the abdomen. The gallbladder was detorted and returned to the anatomical position, after which a routine laparoscopic cholecystectomy was performed. This case highlights the need to retain a high index of suspicion for gallbladder volvulus especially in elderly patients, without known gallstones, with a history of colicky pain and imaging features suggestive of torsion.
- 24 September 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (9) , e273336
Surgical management of gallbladder volvulus
An elderly female in her 80s presented to the Emergency Department with abdominal pain and vomiting, following episodes of intermittent colicky abdominal pain over the preceding 3 days. On examination she was exquisitely tender over a palpable gallbladder in the mid epigastric region. The patient underwent cross-sectional imaging suggestive of acute acalculous cholecystitis and significant hydrops with possible perforation. On review of the images, a suspicion of gallbladder volvulus resulted in emergency need for intervention. At laparoscopy, a diagnosis of gallbladder volvulus was confirmed, with a grossly distended, necrotic gallbladder noted on entry into the abdomen. The gallbladder was detorted and returned to the anatomical position, after which a routine laparoscopic cholecystectomy was performed. This case highlights the need to retain a high index of suspicion for gallbladder volvulus especially in elderly patients, without known gallstones, with a history of colicky pain and imaging features suggestive of torsion.
- Open Access
- 20 July 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 13
Clinician and patient attitudes toward locoregional treatment of oligometastatic oesophago-gastric cancers: a mixed-methods study
- 20 July 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 13
Open AccessClinician and patient attitudes toward locoregional treatment of oligometastatic oesophago-gastric cancers: a mixed-methods study
- Open Access
- 13 July 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or gemcitabine-nab-paclitaxel: a multinational analysis
Background: The survival benefit of adjuvant chemotherapy (AC) for pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection remains controversial. Previous studies often pooled diverse disease stages or chemotherapy regimens, potentially obscuring regimen-specific outcomes. We sought to investigate the association of AC with overall survival (OS) among patients with resected borderline resectable or locally advanced pancreatic cancer (BRPC/LAPC), stratified by specific neoadjuvant and adjuvant regimens. Methods: This multinational, retrospective cohort study included 834 patients with BRPC/LAPC who underwent curative-intent resection following NAT with either FOLFIRINOX or gemcitabine plus nab-paclitaxel (Gem/Nab). Propensity score matching (1:1) was utilized to minimize selection bias. The primary outcome was OS, analyzed using Kaplan-Meier methods and Cox proportional hazards models. Results: Among 834 patients, 605 received neoadjuvant FOLFIRINOX and 229 received neoadjuvant Gem/Nab. In the matched analysis for the neoadjuvant FOLFIRINOX cohort, continuation of adjuvant FOLFIRINOX was associated with longer OS compared with no AC (median OS = 42.0 vs 25.8 months; hazard ratio [HR] = 0.58; 95% confidence interval [CI] = 0.43 to 0.79; P < .001). In contrast, switching to adjuvant Gem/Nab did not confer a survival benefit in this group (HR = 0.84; 95% CI = 0.61 to 1.15; P = .27). For patients receiving neoadjuvant Gem/Nab, adjuvant Gem/Nab or other regimens was not associated with improved OS (HR = 0.92; 95% CI = 0.64 to 1.34; P = .69). Conclusion(s): Survival benefits of adjuvant chemotherapy in resected BRPC/LAPC may be regimen-dependent. Postoperative continuation of FOLFIRINOX appeared to be associated with a survival advantage, whereas regimen deescalation or adjuvant chemotherapy following neoadjuvant Gem/Nab demonstrated no clear benefit.
- 13 July 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Open AccessBenefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or gemcitabine-nab-paclitaxel: a multinational analysis
Background: The survival benefit of adjuvant chemotherapy (AC) for pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection remains controversial. Previous studies often pooled diverse disease stages or chemotherapy regimens, potentially obscuring regimen-specific outcomes. We sought to investigate the association of AC with overall survival (OS) among patients with resected borderline resectable or locally advanced pancreatic cancer (BRPC/LAPC), stratified by specific neoadjuvant and adjuvant regimens. Methods: This multinational, retrospective cohort study included 834 patients with BRPC/LAPC who underwent curative-intent resection following NAT with either FOLFIRINOX or gemcitabine plus nab-paclitaxel (Gem/Nab). Propensity score matching (1:1) was utilized to minimize selection bias. The primary outcome was OS, analyzed using Kaplan-Meier methods and Cox proportional hazards models. Results: Among 834 patients, 605 received neoadjuvant FOLFIRINOX and 229 received neoadjuvant Gem/Nab. In the matched analysis for the neoadjuvant FOLFIRINOX cohort, continuation of adjuvant FOLFIRINOX was associated with longer OS compared with no AC (median OS = 42.0 vs 25.8 months; hazard ratio [HR] = 0.58; 95% confidence interval [CI] = 0.43 to 0.79; P < .001). In contrast, switching to adjuvant Gem/Nab did not confer a survival benefit in this group (HR = 0.84; 95% CI = 0.61 to 1.15; P = .27). For patients receiving neoadjuvant Gem/Nab, adjuvant Gem/Nab or other regimens was not associated with improved OS (HR = 0.92; 95% CI = 0.64 to 1.34; P = .69). Conclusion(s): Survival benefits of adjuvant chemotherapy in resected BRPC/LAPC may be regimen-dependent. Postoperative continuation of FOLFIRINOX appeared to be associated with a survival advantage, whereas regimen deescalation or adjuvant chemotherapy following neoadjuvant Gem/Nab demonstrated no clear benefit.
- Open Access
- 13 June 2026
- Published by Elsevier in Clinical Surgical Oncology
- Vol. 5 (3)
Can GLP-1RA Be Utilised for Pre-operative Liver Optimisation Prior to Hepatectomy? A Scoping Review of MASLD Evidence with Surgical Translation
- 13 June 2026
- Published by Elsevier in Clinical Surgical Oncology
- Vol. 5 (3)
Open AccessCan GLP-1RA Be Utilised for Pre-operative Liver Optimisation Prior to Hepatectomy? A Scoping Review of MASLD Evidence with Surgical Translation
- Open Access
- 12 May 2026
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 10 (3)
Negative-pressure wound therapy in thoracic and abdominal surgery: meta-analysis of randomized trials
Background: Around 30 000 patients undergo emergency laparotomy in the UK each year, and a similar number of patients undergo open cardiothoracic surgery. Surgical site infection is a common complication associated with increased morbidity, prolonged hospital stay, and higher healthcare costs. Negative-pressure wound therapy has been proposed as a prophylactic strategy to reduce wound complications, but trial evidence has been inconsistent. Methods: This systematic review and meta-analysis was carried out using PRISMA guidelines and was registered prospectively in PROSPERO (CRD420251010516). A literature search was carried out in March 2025 (updated December 2025), and titles and abstracts were screened against predefined inclusion criteria. Trials assessing patients undergoing open thoracic or abdominal surgery for any indication in adult patients assessing the risk of surgical site infection as an outcome were included. Quality assessment was performed using Cochrane’s risk-of-bias 2 tool. Summary statistics for outcomes of interest underwent meta-analyses to a confidence interval of 95% and are presented as forest plots. Results: Some 12 427 patients across 45 randomized trials in abdominal and thoracic surgery were included for analysis. Negative-pressure wound therapy significantly reduced surgical site infection compared with standard dressings (odds ratio (OR) 0.53, 95% confidence interval 0.42 to 0.66). The effect was consistent across commercial devices (PICO™ and Prevena™). Negative-pressure wound therapy was associated with shorter hospital stay (mean difference −1.67 (95% confidence interval −3.19 to −0.16) days), but not with reduced risk of organ/space infection (OR 0.92, 0.67 to 1.25), wound dehiscence, or reoperation. Only three studies included thoracic surgery and no significant difference in surgical site infection was found (OR 0.44, 0.00 to 45.25). Publication bias was detected; trim-and-fill analysis attenuated but did not eliminate the benefit (adjusted OR 0.70, 0.54 to 0.90). Adverse events and patient-reported outcomes were reported infrequently, and showed no consistent differences. Conclusion: Negative-pressure wound therapy was associated with a nearly 50% reduction in SSI and shorter hospital stay after open abdominal surgery, with consistent benefit across device types. However, evidence of publication bias, and limited long-term and patient-reported outcome data suggest that effect size may be overestimated. Selective use in high-risk patients is supported.
- 12 May 2026
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 10 (3)
Open AccessNegative-pressure wound therapy in thoracic and abdominal surgery: meta-analysis of randomized trials
Background: Around 30 000 patients undergo emergency laparotomy in the UK each year, and a similar number of patients undergo open cardiothoracic surgery. Surgical site infection is a common complication associated with increased morbidity, prolonged hospital stay, and higher healthcare costs. Negative-pressure wound therapy has been proposed as a prophylactic strategy to reduce wound complications, but trial evidence has been inconsistent. Methods: This systematic review and meta-analysis was carried out using PRISMA guidelines and was registered prospectively in PROSPERO (CRD420251010516). A literature search was carried out in March 2025 (updated December 2025), and titles and abstracts were screened against predefined inclusion criteria. Trials assessing patients undergoing open thoracic or abdominal surgery for any indication in adult patients assessing the risk of surgical site infection as an outcome were included. Quality assessment was performed using Cochrane’s risk-of-bias 2 tool. Summary statistics for outcomes of interest underwent meta-analyses to a confidence interval of 95% and are presented as forest plots. Results: Some 12 427 patients across 45 randomized trials in abdominal and thoracic surgery were included for analysis. Negative-pressure wound therapy significantly reduced surgical site infection compared with standard dressings (odds ratio (OR) 0.53, 95% confidence interval 0.42 to 0.66). The effect was consistent across commercial devices (PICO™ and Prevena™). Negative-pressure wound therapy was associated with shorter hospital stay (mean difference −1.67 (95% confidence interval −3.19 to −0.16) days), but not with reduced risk of organ/space infection (OR 0.92, 0.67 to 1.25), wound dehiscence, or reoperation. Only three studies included thoracic surgery and no significant difference in surgical site infection was found (OR 0.44, 0.00 to 45.25). Publication bias was detected; trim-and-fill analysis attenuated but did not eliminate the benefit (adjusted OR 0.70, 0.54 to 0.90). Adverse events and patient-reported outcomes were reported infrequently, and showed no consistent differences. Conclusion: Negative-pressure wound therapy was associated with a nearly 50% reduction in SSI and shorter hospital stay after open abdominal surgery, with consistent benefit across device types. However, evidence of publication bias, and limited long-term and patient-reported outcome data suggest that effect size may be overestimated. Selective use in high-risk patients is supported.
- Open Access
- 1 March 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (5) , 109732
Simultaneous versus delayed resection of synchronous colorectal liver metastases: A systematic review and meta-analysis
- 1 March 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (5) , 109732
Open AccessSimultaneous versus delayed resection of synchronous colorectal liver metastases: A systematic review and meta-analysis
- Open Access
- 1 February 2025
- Published by AME Publishing Company in AME Surgical Journal
- Vol. 5, 7
A commentary on: “Effect of Preoperative Autologous Blood Storage in Major Hepatectomy for Perihilar Malignancy: A Randomized Controlled Trial”
A commentary on: “Effect of Preoperative Autologous Blood Storage in Major Hepatectomy for Perihilar Malignancy: A Randomized Controlled Trial”
- 1 February 2025
- Published by AME Publishing Company in AME Surgical Journal
- Vol. 5, 7
Open AccessA commentary on: “Effect of Preoperative Autologous Blood Storage in Major Hepatectomy for Perihilar Malignancy: A Randomized Controlled Trial”
A commentary on: “Effect of Preoperative Autologous Blood Storage in Major Hepatectomy for Perihilar Malignancy: A Randomized Controlled Trial”
- Open Access
- 2 August 2024
- Published by Frontiers Media SA in Transplant International
- Vol. 37, 13030
Prophylactic Peri-Nephric Drain Placement in Renal Transplant Surgery: A Systematic Review and Meta-Analysis
Renal transplantation is common worldwide, with >25,000 procedures performed in 2022. Usage of prophylactic perinephric drains is variable in renal transplantation; drains are associated with risks, and there is a lack of consensus regarding benefit of routine drain placement in these patients. This meta-analysis assessed whether prophylactic drainage reduced need for reintervention postoperatively. This systematic review and meta-analysis was carried out using the Preferred Reporting Items in Systematic Reviews and Meta-Analysis, and prospectively registered on PROSPERO. Summary statistics for outcomes of interest underwent meta-analyses to a confidence interval (CI) of 95% and are presented as Forest Plots for Odds Ratio (OR). A systematic literature search in June 2023 revealed 1,540 unique articles across four databases. Of these, four retrospective cohort studies were selected. Meta-analysis of three studies showed no significant reduction in reintervention rate with pre-emptive drain placement, OR = 0.59 (95% CI: 0.16–2.23), p = 0.44. Meta-analysis did not show a significant reduction in perinephric collections with prophylactic drain insertion OR = 0.55 (95% CI: 0.13–2.37), p = 0.42. Finally, there is not good evidence that drain placement reduces superficial wound complications or improves 12-month graft survival. Further work is needed, including well-designed, prospective studies to assess the risks and benefits of drain placement in these patients.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023422685, Identifier PROSPERO CRD42021255795.
- 2 August 2024
- Published by Frontiers Media SA in Transplant International
- Vol. 37, 13030
Open AccessProphylactic Peri-Nephric Drain Placement in Renal Transplant Surgery: A Systematic Review and Meta-Analysis
Renal transplantation is common worldwide, with >25,000 procedures performed in 2022. Usage of prophylactic perinephric drains is variable in renal transplantation; drains are associated with risks, and there is a lack of consensus regarding benefit of routine drain placement in these patients. This meta-analysis assessed whether prophylactic drainage reduced need for reintervention postoperatively. This systematic review and meta-analysis was carried out using the Preferred Reporting Items in Systematic Reviews and Meta-Analysis, and prospectively registered on PROSPERO. Summary statistics for outcomes of interest underwent meta-analyses to a confidence interval (CI) of 95% and are presented as Forest Plots for Odds Ratio (OR). A systematic literature search in June 2023 revealed 1,540 unique articles across four databases. Of these, four retrospective cohort studies were selected. Meta-analysis of three studies showed no significant reduction in reintervention rate with pre-emptive drain placement, OR = 0.59 (95% CI: 0.16–2.23), p = 0.44. Meta-analysis did not show a significant reduction in perinephric collections with prophylactic drain insertion OR = 0.55 (95% CI: 0.13–2.37), p = 0.42. Finally, there is not good evidence that drain placement reduces superficial wound complications or improves 12-month graft survival. Further work is needed, including well-designed, prospective studies to assess the risks and benefits of drain placement in these patients.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023422685, Identifier PROSPERO CRD42021255795.
- Open Access
- 12 June 2024
- Published by Springer Nature in Surgical Case Reports
- Vol. 10 (1) , 1-7
Migrated tubal sterilisation clip presenting as a subcutaneous gluteal foreign body 24 years later: a case report and literature review
Background: The incidence of sterilisation clip migration is reportedly 25%. However, less than 1% of those who experience clip migration will present with pain, an abscess, or spontaneous extrusion. Here we present a rare case of sterilisation clip migration through the entire pelvic floor. Case presentation: A 66-year-old female was referred from community to the Surgical Emergency Unit with a possible metallic foreign body under the skin following an attempted routine gluteal cyst excision. The patient first noticed a lump under the skin 2 years ago which gradually became more apparent and tender over the previous 2 months. The patient denied recent trauma, had no co-morbidities and had a sterilisation procedure 24 years prior. Examination revealed a non-mobile solid structure just beneath the skin 5 cm laterally from the anal verge. Inflammatory markers were normal and an ultrasound confirmed a 15 × 7 mm foreign body in the subcutaneous tissues. The foreign body was excised easily under local anaesthesia, revealing a closed Filshie sterilisation clip. The wound was closed primarily, and recovery was uncomplicated. Conclusions: This was a case of sterilisation clip migration to the subcutaneous gluteal region. A literature review revealed 34 case reports of sterilisation clip migration, mostly to the bladder. Patients with a previous sterilisation procedure and suspected subcutaneous foreign body without trauma should elicit a high index of suspicion for migrated sterilisation clips. These clips can migrate through multiple layers of muscle and fascia, including the pelvic floor.
- 12 June 2024
- Published by Springer Nature in Surgical Case Reports
- Vol. 10 (1) , 1-7
Open AccessMigrated tubal sterilisation clip presenting as a subcutaneous gluteal foreign body 24 years later: a case report and literature review
Background: The incidence of sterilisation clip migration is reportedly 25%. However, less than 1% of those who experience clip migration will present with pain, an abscess, or spontaneous extrusion. Here we present a rare case of sterilisation clip migration through the entire pelvic floor. Case presentation: A 66-year-old female was referred from community to the Surgical Emergency Unit with a possible metallic foreign body under the skin following an attempted routine gluteal cyst excision. The patient first noticed a lump under the skin 2 years ago which gradually became more apparent and tender over the previous 2 months. The patient denied recent trauma, had no co-morbidities and had a sterilisation procedure 24 years prior. Examination revealed a non-mobile solid structure just beneath the skin 5 cm laterally from the anal verge. Inflammatory markers were normal and an ultrasound confirmed a 15 × 7 mm foreign body in the subcutaneous tissues. The foreign body was excised easily under local anaesthesia, revealing a closed Filshie sterilisation clip. The wound was closed primarily, and recovery was uncomplicated. Conclusions: This was a case of sterilisation clip migration to the subcutaneous gluteal region. A literature review revealed 34 case reports of sterilisation clip migration, mostly to the bladder. Patients with a previous sterilisation procedure and suspected subcutaneous foreign body without trauma should elicit a high index of suspicion for migrated sterilisation clips. These clips can migrate through multiple layers of muscle and fascia, including the pelvic floor.
- Open Access
- 28 June 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (10) , 3078-3086
Autologous blood transfusion reduces the requirement for perioperative allogenic blood transfusion in patients undergoing major hepatopancreatobiliary surgery: a retrospective cohort study
Introduction: Major hepatopancreatobiliary surgery is associated with a risk of major blood loss. The authors aimed to assess whether autologous transfusion of blood salvaged intraoperatively reduces the requirement for postoperative allogenic transfusion in this patient cohort. Materials and methods: In this single centre study, information from a prospective database of 501 patients undergoing major hepatopancreatobiliary resection (2015–2022) was analysed. Patients who received cell salvage (n=264) were compared with those who did not (n=237). Nonautologous (allogenic) transfusion was assessed from the time of surgery to 5 days postsurgery, and blood loss tolerance was calculated using the Lemmens–Bernstein–Brodosky formula. Multivariate analysis was used to identify factors associated with allogenic blood transfusion avoidance. Results: 32% of the lost blood volume was replaced through autologous transfusion in patients receiving cell salvage. Although the cell salvage group experienced significantly higher intraoperative blood loss compared with the noncell salvage group (1360 ml vs. 971 ml, P=0.0005), they received significantly less allogenic red blood cell units (1.5 vs. 0.92 units/patient, P=0.03). Correction of blood loss tolerance in patients who underwent cell salvage was independently associated with avoidance of allogenic transfusion (Odds ratio 0.05 (0.006–0.38) P=0.005). In a subgroup analysis, cell salvage use was associated with a significant reduction in 30-day mortality in patients undergoing major hepatectomy (6 vs. 1%, P=0.04). Conclusion: Cell salvage use was associated with a reduction in allogenic blood transfusion and a reduction in 30-day mortality in patients undergoing major hepatectomy. Prospective trials are warranted to understand whether the use of cell salvage should be routinely utilised for major hepatectomy.
- 28 June 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (10) , 3078-3086
Open AccessAutologous blood transfusion reduces the requirement for perioperative allogenic blood transfusion in patients undergoing major hepatopancreatobiliary surgery: a retrospective cohort study
Introduction: Major hepatopancreatobiliary surgery is associated with a risk of major blood loss. The authors aimed to assess whether autologous transfusion of blood salvaged intraoperatively reduces the requirement for postoperative allogenic transfusion in this patient cohort. Materials and methods: In this single centre study, information from a prospective database of 501 patients undergoing major hepatopancreatobiliary resection (2015–2022) was analysed. Patients who received cell salvage (n=264) were compared with those who did not (n=237). Nonautologous (allogenic) transfusion was assessed from the time of surgery to 5 days postsurgery, and blood loss tolerance was calculated using the Lemmens–Bernstein–Brodosky formula. Multivariate analysis was used to identify factors associated with allogenic blood transfusion avoidance. Results: 32% of the lost blood volume was replaced through autologous transfusion in patients receiving cell salvage. Although the cell salvage group experienced significantly higher intraoperative blood loss compared with the noncell salvage group (1360 ml vs. 971 ml, P=0.0005), they received significantly less allogenic red blood cell units (1.5 vs. 0.92 units/patient, P=0.03). Correction of blood loss tolerance in patients who underwent cell salvage was independently associated with avoidance of allogenic transfusion (Odds ratio 0.05 (0.006–0.38) P=0.005). In a subgroup analysis, cell salvage use was associated with a significant reduction in 30-day mortality in patients undergoing major hepatectomy (6 vs. 1%, P=0.04). Conclusion: Cell salvage use was associated with a reduction in allogenic blood transfusion and a reduction in 30-day mortality in patients undergoing major hepatectomy. Prospective trials are warranted to understand whether the use of cell salvage should be routinely utilised for major hepatectomy.